Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
In a tangential note to you mentioning holding shares of a possible acquiring company. If the acquisition price is significant enough (>$5 per share), it would definitely be preferable to have the deal go down as cash + shares, or just shares, as that would enable postponing to a degree cap gains taxes and minimizing higher income effects to other things such as Medicare premiums escalation.
Exactly…I get the rationale for choosing PFE in Canada as a partner but to your point, in the hierarchy of what the reps carry in their bags, V was probably somewhere in the bottom. Given limited time with physicians, reps are lucky to bring up two drugs in their bag. Even an army of sales reps can’t change that dynamic since a million times 0 is still zero (well you get the analogy)
Ram, do you really think that a bunch of Monday-morning quarterbacks on an anonymous internet forum know more about the scientific studies being done on IPE than the scientists that run the largest provider of IPE?
Honestly, that's crazy-talk.
The one thing we do know is that we don't know if they did any research on this already.
Not necessarily. What this highlights is the poor return of partnerships. I believe JT mentioned this dynamic when considering partnerships in the EU. V just becomes one out of a hundred other drugs in the salesperson’s bag. Plus they will usually focus their efforts on pushing the drugs that are most profitable to their company. Only way BP really pushes V is if they own it.
J.T. had intentions of making Amarin into a BP by using Vascepa revenues to develop new indications for EPA meds and to acquire additional meds...Now Denner has intentions of selling Amarin to a BP with more assets
In retrospect, I believe that Amarin could actually have become a BP if everything hadn't came crashing down, due to the judge DU decision and the lack of U.S. courts' enforcement of infringement laws...I hope that Denner is more successful than J.T. was and I look forward to holding shares in the fortunate acquiring BP.
No, just Pfizer no longer selling for HLS.
There’s been a lot of talk on this board and others about the “bioavailability” of generic VASCEPA® vs. the brand. Personally, I don’t believe the end generic product is compositionally equivalent.
Aside from that, one critical issue that is seldom mentioned is the fact that pure EPA begins to oxidize immediately and becomes less efficacious the longer it remains apart from its site of uptake in the blood stream. Encapsulation is a method of slowing this process down. However, even this won’t prevent oxidation from eventually destroying the intended use.
Fortunately, Amarin has patented a capsule that inhibits oxidation much more effectively than the standard gel cap.
You may pay slightly less for the generic, but your savings just might be in determent to your life and health.
So now we are out of canada? Man what will it take to even get a hint of good news for AMRN.
Honestly, I don't think one has anything do with the other. The sales/distribution methods in Europe are much different than Canada and the US.
I agree, Vascepa has been a bit of a disappointment in Canada. $17-18M in full-year revenue after this many years is pretty disappointing. I wasn't able to listen to the earnings call today, but am hoping to listen to the replay when available.
I think a lot of this goes back to the GIA strategy. HLS is not a big company. They are tiny, and they are boot-strapping it (hence, why they brought in Pfizer originally).
Vascepa in the hands of a BP probably would have gone much differently.
Ziploc, Just tried searching Google patents - very extensive documentation:
https://patents.google.com/patent/WO2023146984A1/en?oq=WO2023146984
Its disappointing that Pfizer is not able to find marketing leverage for Vascepa in Canada primary care !
How will this impact evaluation estimates for other BP's in Europe ??
Its most likely a Bearish sign, neutral at best, and not what I was hoping for !!
I didn't say it was a waste of time and money. I said I don't think that's the direction Sarissa wants to go.
And how can Amarin claim a patent on research they didn't do, using a product that is not even theirs?
I'm not sure why you and Kiwi think this is such a big waste of time and money..... they don't need to chase a migrane indication..... they have the resources to do a quick patent search and if one doesn't exist, apply for the patent and add it to the portfolio for future use.
Published Today: New US Patent Application US 2024/0148683 A1 for the encapsulation of ultra-pure EPA. This is presumably filed to extend the current patent # US 8,642,077 B2 which is set to expire Feb. 4, 2034.
https://ppubs.uspto.gov/dirsearch-public/print/downloadPdf/20240148683
Just a reminder of one of the reasons why generic versions of VASCEPA® which are not encapsulated by this patented method may not be as efficacious as the Real Deal! Don’t trust your health and life to oxidized products!
I have to agree with Kiwi on this. Amarin already knows about the migraine issue. They are aware of anything and everything that goes on with IPE.
But I also don't believe that Amarin has the time, resources, or interest to chase new indications that are not central to their goal. I believe Denner wants to focus on getting V rolled out in Europe, finish out the litigation efforts in the U.S. (whatever might come of that), possibly do something with the new formulations (LrEtEPA, MND-2119), and get this thing sold.
The other indications and formulations...colorectal cancer, migraines, FDC, etc. are likely something to be dangled in front of a BP as a future opportunity.
I may be wildly wrong, but there does not seem to be any effort or money being spent on R&D right now, which would be the big indicator that something was going on.
As I have stated previously about the lack of traction in Canada, it was only a matter of time before HLS needed to do something.
Pfizer was responsible for less than $6M in revenue annually, IIRC. They essentially weren't selling anything.
On a more positive note, HLS highlights in Canada included:
Vascepa unit demand increased by 54% compared to Q1 2023.
The number of consistent prescribers2 for Vascepa increased 112% compared to Q1 2023.
Vascepa net revenue was C$4.5 million, up 27% compared to C$3.5 million in Q1 2023.
Here is a summary of Amarin's patents on LR-EtEPA
Abstract of patents WO2023146984
"Lymph-releasing compositions of fatty acids and uses thereof for lymphatic incorporation and systemic disease treatment
Abstract
Provided are compositions comprising one or more polyunsaturated fatty acids or derivatives thereof, a source of phospholipid, and optionally one or more additional emulsifiers, as well as methods of using the same to treat various diseases. In some embodiments, provided is a lymph-releasing composition of eicosapentaenoic acid ethyl ester (LR-EtEPA) and methods of using the same to increase EPA uptake in tissues and to treat various diseases including cardiopulmonary diseases, renal diseases, neurological diseases, and CANCER."
HLS in Canada has terminated their agreement with Pfizer effective May 1st!!
"We have been closely examining the performance of our go-to-market model in primary care. We have concluded that the ROI for this model remains unprofitable and, despite best efforts, there are not enough signs of improvement to justify continuing at our current level of investment. As a result, we have provided Pfizer with a notice of termination of the Agreement between the two companies. We are working with them on an orderly wind down and transition back to HLS of all primary care related activities which we expect will be completed during the second half of 2024. We thank Pfizer for the commitment and effort that they have made towards trying to make this go-to-market model successful."
Yep, could have used VASCEPA 16 years ago when I had my prostate removed!
You are by far the best advocate for AMRN.
Captain,
Thank you for keeping us abreast on PREPARE RCT (PRevention Using EPA Against coloREctal).
As a reminder, Amarin’s Form 10-K 2022 for the year ending December 31, 2021 asserts that the Company "owns" "one additional patent related to the use of VASCEPA to treat prostate cancer with a term that expires in 2037."
Trust me, there’s going to be enough heart disease to go around for everybody.
Then they better get moving, don't you think! ...... they just need to apply for it Kiwi...... get the app in first...... they won't even own the company by the time it's approved so who cares? BP will follow up.
Nope ...good news for the new weight loss drugs
Now if Vascepa could be proven to reduce obesity ...then you're talking
Kiwi
Good news for the future of Amarin and Vascepa I guess.
https://www.nbcnews.com/health/heart-health/adults-us-heart-diabetes-syndrome-risk-research-rcna151215
Ram. it typically takes 1-5 yrs to get a patent on a drug . You're dealing with prior art and USPTO actions .
IIRC in the 2010 / 2011 period the patent office originally rejected the Marine patent . Eventually it was approved because AMRN could prove that Vascepa ( AMR101 at the time ) was DEVOID of DHA . Epadel by contrast has up to 10% DHA .
Poster North may have a better memory of this period.
AMRN doesn't have this time if they continue on their current path and especially if they use $50m on a share buyback.
The reality is that revenue in the US is crashing and revenue growth in the EU is minuscule .
And so far mgt has yet to come up with an effective plan to convince the market , they can change that .
Which is why the PPS is under $1.
JMO
Kiwi
Ramfan, Does anyone else have a method of use patent, that covers icosapent ethyl, for migraine treatment?
Sleven,
Why wouldn't they spend time and money on a patent....... it's not that much time and it's not that much money. They don't have to do any lengthy study either..... just get the patent and add it to your patent portfolio to increase the value of the company.
I hope that management is well informed and aware of the opportunities that this study will provide.
Because Dr Ketchum probably knows this already ...and knows AMRN will not spend time and $ on pursuing this since for one thing they would need to prove it better than an EPA/DHA combination .
So, why are you telling me all this? These things I already know. Again my point to relaying this to Amarin is to inform them of a possible patent they could get priority on. Indications which already have studies on the drug you own are low hanging fruit. Don't let the competition snag an IP that you should get the first crack at.
Capt. I believe thats a lot of Prior Art regarding Omega 3's and migraines ...so patent protection might be a challenge.
The exclusivity route ...see previous posts .
Great graphics tho
Kiwi
So I'll answer my own question about lack of patent protect for the migraine indication...exclusivity is an option
There's a plethora of indications that could be studied. What would I have Amarin do? Figure out which indications are hanging fruit and get those patent applications submitted. My reason for pointing these things out to them is because I'm not sure they're even aware of this stuff. Maybe they'll see the good work I do and offer me a job in PR? lol
CaptBeer
Yet another reason for the 10 % drop for us When will it ever end ? I mean OMG we cannot even be at 1 dollar so sad . Less then 2 million shares traded what happens when its 40/50 million shares ?
Michael
EPA is a med that needs development ASAP, not only for the CVD indication, but also for several other indications...If Amarin is unable to perform this task, Amarin should be sold to a BP that has the necessary assets to do it.
My apologies for my mistake. I was looking at JAMA Network link, not the link you had referred to.
JR, You are an Ok guy 'some days' - when your not focusing on Sarissa and Denner 'cheating everyone' in the market 🙂
---------------------------------
Here trying to solve the confusion - olive oil / EPA Vascepa for North - 'no spring hare' !
Capt. What would you have AMRN do with this info ?
AMRN doesn't have any patents covering composition or method of action for treating migraines that I'm aware of .
The trial was run using Epadel ...and it only enrolled 70 people using a drug not FDA regulated
ralphey, You seriously are in need of psychological help.
You spending time on a random financial forum - where you clearly have no idea of what is actually going on - calls for a serios mental problem !
--------------------------------
You go find a qualified psychiatrist - who know which best drugs to help you - and in a few months - you will again be able to appreciate being alive 🙂
Captain, Let me know if you get a response.
Thanks.
Sleven,
yep. I sent this link and my slides to Amarin. They need to get eyes on this. The CRC study is another one that they need to move on.
Captain,
https://www.sciencedirect.com/science/article/pii/S0889159124003003
Journal publication.
Sleven,
The Treatment Arm consisted of:
(2) 1g capsules of EPA (900mg), DHA (10mg), other FA's (90mg) * note although not specifically named this is the formulation of EPADEL.
The Placebo Arm was 100% Soybean Oil
DYK that EPA significantly reduces the number of migraine attacks and their severity. Who knew?https://t.co/SLwMWHqegK
— Mike Everts (@GeoWizz_) May 8, 2024
@Amarincorp @SABOURETCardio @DLBHATTMD @drpablocorral @mmillermd1 @VietHeartPA @MarkBrady2014 pic.twitter.com/tSz3wGPuMr
CCI.
Clown contrarian indicator
Yeah, what’s with the beat down today?
Ralphey,
You are bitter. We are all sad and disappointed, but it serves no purpose to get bitter.
Followers
|
1106
|
Posters
|
|
Posts (Today)
|
1
|
Posts (Total)
|
428910
|
Created
|
03/12/07
|
Type
|
Free
|
Moderators ziploc_1 zmanindc Number sleven |
AMARIN TICKER RELATED LINKS
Amarin Webpage
NASDAQ AMRN Quote
Y! Finance AMRN Landing Page
Seeking Alpha AMRN Landing Page
FinViz AMRN Landing Page
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |